Kimberline Gerrick Email & Phone Number

Chicago, Il, Us

Chicago, Il, Us

Sunnyvale, California, Us

Project Team and Biomarker Leader for clinical stage immuno-oncology asset, 23ME-01473 (anti-ULBP6 antibody), from IND clearance through ongoing Ph1/2 study.Responsible for strategic planning and execution of program goals, timelines, and budget by aligning cross-functional teams (e.g. biology, translational sciences, CMC, CSC, clinical operations, clinical science, clinical pharmacology, regulatory, quality).Developed and oversaw implementation of preclinical translational and clinical biomarker strategies, which included identification of target patient population, PD biomarkers, and combination partners, internally and at CROs.Manager of 3 scientists responsible for biomarker and PK bioanalysis across two clinical stage assets, 23ME-01473 and 23ME-00610 (anti-CD200R1 antibody).Developed program publication strategy; lead presenter and author of 3 pre-clinical presentations at international congresses (including an oral presentation at AACR) and corresponding author on a manuscript for peer review.Lead author of nonclinical pharmacology summaries and biomarker sections of IND filing documents.Collaborated across the clinical development team for Phase 1 study start-up activities, including vendor selection and authoring sections of clinical documents.Supported due diligence and external partnering and business development meetings as the biology and biomarker subject-matter expert.

Sunnyvale, California, Us

South San Francisco, California, Us

Translational Science Leader for two oncology assets, IDE397 (MAT2A small molecule inhibitor in Phase 1/2) and a preclinical asset.Oversaw the translational biology and clinical biomarker strategies for the IDE397 program.Responsible for analysis and presentation of pre-clinical and clinical biomarker data to senior leadership and external pharma collaborators to guide clinical development of IDE397.Collaborated with clinical and biomarker operations teams to provide guidance on clinical sample collections, patient enrollment strategies, and Investigational Brochure submissions.Designed and executed cell-based assays to evaluate drug potency, target engagement, mechanism of action, and indication prioritization to support a preclinical asset.Managed a Scientist and a Principal Research Associate responsible for preclinical predictive and PD biomarker discovery.

South San Francisco, California, Us

Hayward, California, Us

Pharmacodynamics Team Leader for Phase 1 studies of immuno-oncology assets, Quemliclustat (CD73 small molecule inhibitor) and Etrumadenant (A2AR/A2BR small molecule inhibitor).Responsible for the development and employment of soluble biomarker and receptor occupancy target engagement assays, and exploratory peripheral blood immune profiling for adenosine pathway and TIGIT-targeting assets for oncology.Managed a Research Associate II responsible for receptor occupancy assays conducted in clinical stage AB122 (anti-PD-1) program

Hayward, California, Us

Baltimore, Md, Us

Advisor: Elizabeth Jaffee, MDI studied epigenetic and genetic regulators of human macrophage polarization.

Irvine, Ca, Us

Dr. Shiou-Chuan (Sheryl) Tsai lab

Doctor Of Philosophy - Phd, Cellular And Molecular Medicine

Bachelor Of Science - Bs, Biochemistry And Molecular Biology